Categories: All postsCannabis

HEXO is an interesting play in the pot sector, James Hodgins says

James Hodgins
Pot stocks have taken a beating over the past couple of months as the emerging industry still tries to find its feet, but one company that seems to have hit the ground running is HEXO Corp (HEXO Corp Stock Quote, Chart TSX:HEXO), which just closed on a $321-million acquisition of cannabis company Newstrike Brands.

Fund manager James Hodgins says one of HEXO’s strengths is in edibles, which are expected to make a big impact when they come online later this year.

“We like HEXO and we own a little bit. It’s been kind of an under-the-radar name,” said Hodgins, chief investment officer at Curvature Hedge Strategies, in conversation with BNN Bloomberg on Friday.

Hodgins says he favours both Gatineau, Quebec’s HEXO and Moncton, New Brunswick’s Organigram. “They certainly have their niche markets and HEXO has the sprays and edibles and they seem to be specializing in that and it seems to be working for them,” he says.

After a brilliant start to the year, the pot sector has faltered in recent weeks, HEXO included. The Horizons Marijuana Life Sciences ETF, which attempts to mirror the North American cannabis industry as a whole, gained almost 65 per cent between the start of January and mid March but has tumbled 21 per cent since March 19. HEXO’s share price climbed 139 per cent between January 1 where it stood at $4.61 and April 29 when it hit $11.29, but it has since pulled back, closing at $8.67 last Friday.

Hodgins says the sector could experience further declines.

“I think that the space itself is overbought,” he says. “Last summer there was a huge drawdown in the space as liquidity came out and speculation waned but that all changed with the [Constellation Brands] purchase of Canopy Growth and then all of these stocks have done well in the last year, but we’re cautious on the space.”

Ahead of HEXO’s quarterly earnings, due later this month, the company last reported its financials on March 14 when it reported a loss of $4.3 million on revenues of $16.2 million in its second quarter, a 144-per-cent increase in its top line compared to a year earlier.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: hexo
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

6 hours ago

NLH has 173% upside, Echelon says

Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]

6 hours ago

Shopify upgraded to “Buy” at Citi

The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]

7 hours ago

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

3 days ago

Is SNAP a buy right now?

He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]

3 days ago

Bombardier wins price target raise at Desjardins

Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]

3 days ago